Home World News Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients... World News Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin By Ogkologos - February 23, 2026 378 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-905/EV-303 study Source RELATED ARTICLESMORE FROM AUTHOR How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research MOST POPULAR Facing Crisis After Crisis During Cancer: How to Cope April 28, 2022 FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and... February 4, 2026 How Financial Toxicity Can Impact Cancer Caregivers and Where to Find... August 23, 2022 When You Have Cancer and You’re a Parent: “Your Stories” Podcast February 17, 2021 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Tucatinib How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find... How to Strengthen Your Immune System: Part 2 Cancer in My Community: Obstacles to Caring for People With Cancer...